ClinicalTrials.gg
CompletedNCT03432793Updated Jan 14, 2021

Drug-Drug Interaction (DDI) Study for TD-9855

A Phase 1 interventional study of TD-9855 and Fluvoxamine in Drug Drug Interaction (DDI), sponsored by Theravance Biopharma. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-14.

Sponsored by Theravance Biopharma (part of Zymeworks) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.

Enrollment
587th of 785
41 · median 109
Started
2018
with 37 others
Phase 1
67 of 899
3 open now
Registered
593rd of 899
by date

Among the 899 studies in Smoking with a site in United States, this one is the 587th largest by enrollment of the 785 interventional ones that give a count, is one of 38 that started in 2018, is one of 67 in phase 1, and was the 593rd registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Smoking studies recruiting now, 74 (52%) set no upper age limit and 51 (36%) stop at 75 or younger; 3 take children under 18; 68 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 899 studies in Smoking with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.

03

Conditions studied

  • Drug Drug Interaction (DDI)

Browse trials for

Keywords

  • DDI
  • Itraconazole
  • Fluvoxamine
  • TD-9855
  • Smoking
  • Caffeine
  • CYP1A2
  • CYP3A4
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give written, signed
  • Male subjects 19 to 55 years of age (inclusive)
  • 19 to 32 kg/m2 (inclusive), and weigh at least 55 kg
  • No abnormal physical findings as determined by the Principal Investigator (PI) at the screening and Day -1 examinations
  • Negative for virus (HBV), virus (HCV), and (HIV) antibody at screening.
  • No clinically important laboratory abnormalities as determined by the PI
  • Ability to communicate effectively with the Investigator and to comply with all study requirements, restrictions, and direction of the clinic staff
  • Male subjects must abstain from sexual intercourse or use a highly effective method of
  • Male smokers: Subjects who self-report to have smoked > 9 cigarettes per day for at least 6 month prior to screening as confirmed by urine cotinine test at screening and Day -1.
  • Male smokers: Subjects must be willing to continue consistent use of their tobacco products throughout the study.
  • Additional inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Positive for virus (HBV), virus (HCV), and (HIV) antibody at screening.
  • History or presence of respiratory, gastrointestinal, renal, hepatic, hematologic, neurologic (including history of seizure and insomnia), cardiovascular (including postural orthostatic hypotension or tachycardia), psychiatric (including depression and known addictive disorders), musculoskeletal, genitourinary (including urinary retention), immunologic, or dermatologic disorder.
  • Any other condition that, in the opinion of the PI, would confound or interfere with study participation; evaluation of safety, tolerability, or PK of the drug; or prevent compliance with the study protocol
  • Any history of suicide attempts/ideation or current suicidal ideation.
  • Have participated in another clinical trial of an investigational drug (or medical device) within 30 days (or 5 half-lives of the investigational drug if longer than 30 days) prior to Screening, or are currently participating in another trial of an investigational drug (or medical device), or intending to participate in another trial of an investigational drug (or medical device) before completion of all scheduled safety evaluations in this trial
  • Additional inclusion criteria apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    TD-9855 + Fluvoxamine + Caffeine

    Male smokers will receive TD-9855, fluvoxamine, and caffeine

    Drug: TD-9855 · Drug: Fluvoxamine · Drug: Caffeine

  • Experimental
    TD-9855 + Itraconazole + Caffeine

    Male non-smokers will receive TD-9855, itraconazole, and caffeine

    Drug: TD-9855 · Drug: Itraconazole · Drug: Caffeine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine

    Time frame: Day 9 and Day 24

Secondary outcomes

  1. Correlation between caffeine PK disposition and TD-9855 plasma exposure

    Correlation co-efficient will be calculated between caffeine/paraxanthine ratio at 4hr after caffeine dose and TD-9855 plasma AUC on Day 9 and Day 24.

    Time frame: Day 9 and Day 24

07

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2018, 1 month.

Of 34 phase 1 interventional studies under Smoking, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 49. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2018
First posted
Feb 14, 2018
StartActual
Feb 28, 2018
Primary completionActual
Apr 21, 2018
CompletionActual
Apr 21, 2018
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03432793
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Feb 28, 2018
Primary completion
Apr 21, 2018
Completion
Apr 21, 2018
Last update
Jan 14, 2021

Study contacts

Medical Monitor
study director · Theravance Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ampreloxetine · Fluvoxamine

Start the discussion